Fate Therapeutics (FATE) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Fate Therapeutics (FATE) has outperformed SAB Biotherapeutics (SABS) over the past year, gaining 54.7% versus a gain of 23.1%. Over five years, FATE leads with a -96.5% price change compared with -97.1% for SABS. SAB Biotherapeutics is the larger company by market cap ($262.0 million vs $257.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | SABS |
|---|---|---|
| Share price | $2.15 | $2.88 |
| Market cap | $257.61M | $262.04M |
| 1-day change | -6.11% | -1.71% |
| YTD return | +119.39% | -22.99% |
| 1-year return | +54.68% | +23.08% |
| 5-year return | -96.49% | -97.15% |
| EPS (TTM) | $-1.05 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $5.15 |
| 52-week low | $0.95 | $2.10 |
| Distance from 52-week high | -33.44% | -44.08% |
| Average volume | 1.90M | 495.86K |
| Shares outstanding | 119.82M | 90.99M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed SABS by 31.6 percentage points over the past year.
FATE vs SABS FAQ
Which is bigger, Fate Therapeutics or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $262.04M compared with $257.61M for Fate Therapeutics (FATE).
Which stock has performed better over the past year, FATE or SABS?
FATE returned +54.68% over the past 12 months, compared with +23.08% for SABS (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.